On October 25, 2022 GT Biopharma, Inc. (NASDAQ: GTBP) (the "Company" or "GTB"), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE platform, reported that the Interim Chief Executive Officer and Executive Chairman, Michael Breen, will present a corporate overview to investors at the LD Micro Main Event XV taking place October 25-27, 2022, at the Luxe Sunset Boulevard Hotel in Los Angeles (Press release, GT Biopharma, OCT 25, 2022, View Source [SID1234623367]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast of the company’s presentation on October 26th at 4:30 p.m. PDT, please visit View Source to access the "Track 2" presentation.